Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Frankfurt - Delayed Quote • EUR Onco-Innovations Limited (W1H.F) Follow Add holdings 0.9800 +0.0650 +(7.10%) As of 5:43:41 PM GMT+2. Market Open. All News Press Releases SEC Filings Onco-Innovations' Inka Health Signs New Analytical Work with AstraZeneca Canada to Advance Real-World Evidence in Regulatory Science VANCOUVER, BC / ACCESS Newswire / April 24, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned subsidiary, Inka Health Corp. ("Inka Health"), signed ... Dr. James Orbinski Joins Onco-Innovations' Scientific and Clinical Advisory Board to Bolster Company's Mission VANCOUVER, BC / ACCESS Newswire / April 22, 2025 / Onco-Innovations Limited(CSE:ONCO)(OTCQB:ONNVF) (Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce the appointment of Dr. James Orbinski as a member of the Company's Scientific ... Onco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP Technology PNKP TechnologyShown in Past Study to Increase Survival Rate in Colorectal Cancer Bearing Mice VANCOUVER, BC / ACCESS Newswire / April 17, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company")is ... Onco-Innovations Announces Private Placement Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire / April 16, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") ... Onco-Innovations’ Inka Health Publishes Roche-Sponsored Study Advancing Real-World Oncology Research VANCOUVER, BC / ACCESS Newswire / April 10, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its subsidiary, Inka Health Corp. ("Inka Health"), has published ... Onco-Innovations' Inka Health Completes Analytical Work for AstraZeneca Canada, Advancing Pharmaceutical Analytics and Leading to Key Studies at ISPOR 2025 VANCOUVER, BC / ACCESS Newswire / April 3, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned subsidiary, Inka Health Corp. ("Inka Health"), which ... Onco-Innovations' PKNP Technology Used with Radiation Therapy Shown in Study to Demonstrate Low Toxicity and High Safety Profile VANCOUVER, BC / ACCESS Newswire / March 26, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to provide information regarding its second-generation nanoparticle formulation of ... Onco-Innovations Extends Marketing Program VANCOUVER, BC / ACCESS Newswire / March 25, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announces that it has extended the term of its engagement with MCS Market Communication Service ... Onco-Innovations Provides Update on Use of Proceeds VANCOUVER, BC / ACCESS Newswire / March 24, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H), (WKN: A3EKSZ ) (" Onco " or the " Company "), at the request of the Canadian Securities Exchange, provides, by way of the table below, ... Onco-Innovations CEO Thomas O’Shaughnessy Featured on Conversations That Matter to Discuss Breakthroughs in Cancer Treatment, AI Integration, and Potential Global Expansion VANCOUVER, BC / ACCESS Newswire / March 2, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H)(WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that its CEO, Thomas O'Shaughnessy, was recently featured in an exclusive ... Onco-Innovations' Inka Health Innovative AI-Driven Oncology Study Paves the Way for New Research VANCOUVER, BC / ACCESS Newswire / February 27, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to provide information regarding its wholly-owned subsidiary, Inka Health ("Inka"), ... Onco-Innovations' PKNP Technology Shown in Study to Demonstrate Low Toxicity and High Safety Profile VANCOUVER, BC / ACCESS Newswire / February 24, 2025 / Onco-Innovations Limited(CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information regarding its second-generation nanoparticle formulation of ... Onco-Innovations Provides Information Regarding Inka Health's USPTO Provisional Patent Application for AI-Powered Precision Medicine Platform, SynoGraph VANCOUVER, BC / ACCESS Newswire / February 21, 2025 / Onco-Innovations Limited(CSE:ONCO)(OTCQB:ONNVF) (Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly owned subsidiary, Inka Health ("Inka"), filed a provisional ... Onco-Innovations Announces U.S. Listing on the OTCQB Market VANCOUVER, BC / ACCESS Newswire / February 21, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its common shares have commenced trading on the OTCQB marketplace ... Onco-Innovations' Licensed PNKP Inhibitor Technology Shown to Increase Sensitivity of Cancer Cells to Radiation in Animal Study Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H ,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its exclusive-licensed technology, a new class of Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitors (the "Technology"), ... Onco-Innovations Announces Expression of Interest Between Inka Health and Global Data Leader, Quantify Research VANCOUVER, BC / ACCESS Newswire / February 6, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly-owned subsidiary, Inka Health Corp. ("Inka Health") has entered into ... Onco-Innovations Completes Acquisition of Inka Health to Accelerate AI-Driven Cancer Research and Drug Development Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news release dated January 22, 2025, that it has completed the acquisition (the "Acquisition") of all of the outstanding ... Onco-Innovations' Licensed Technology Shows Promise in Enhancing Chemotherapy Effectiveness by Overcoming Cancer Cell Resistance and Inhibiting Cancer Cell Repair VANCOUVER, BC / ACCESS Newswire / January 30, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its licensed technology of a new class of PNKP (Polynucleotide Kinase ... Onco-Innovations' Private Placement Fully Subscribed VANCOUVER, BC / ACCESS Newswire / January 29, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that its non-brokered private placement (the "Private Placement") of up to 408,164 ... Onco-Innovations Unaware of Any Material Change At the request of the Canadian Investment Regulatory Organization, Onco-Innovations Limited (the "Company") wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent ... Performance Overview Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) Return W1H.F S&P/TSX Composite index (^GSPTSE) YTD +78.18% +1.49% 1-Year +170.57% +14.50% 3-Year +170.57% +20.76%